Deals like Amgen-Horizon won’t necessarily bring US FTC settlement, agency official says
US pharmaceutical deals that are comparable to the Amgen-Horizon transaction, which was resolved via a mid-litigation consent decree with a behavioral remedy, might not be addressed by the Federal Trade Commission...To view the full article, register now.
Already a subscriber? Click here to view full article